Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Clinical trial NCT02252042 · COMPLETED

Trial details

NCT number: NCT02252042
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Cancer

Start date: 2014-11-17
Primary completion: 2017-05-15
Enrollment: 495

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.